Inhibrx Biosciences, Inc.INBX stock score: 38/100
$74.33 · +7.63% · Scored Nov 19, 2026
- Technical
- 29
- Fundamental
- 40
- News
- 58
The reading
Inhibrx Biosciences (INBX) scores 38 out of 100, which reads bearish, higher than 17% of Healthcare stocks and 18% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 40, technicals 29.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Growth (Annual) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 16 and contrarian oscillators 64 — a split worth reading before trusting the technical total.
News sentiment is neutral at 58; it is shown, not counted in the composite.
Since Aug 22, 2026 the composite has ranged from 37 to 56, and it is down 17 points over the period.
About Inhibrx Biosciences
Inhibrx Biosciences (INBX) is a clinical-stage biotechnology company that develops antibody-based therapies for cancer. It was spun off when Sanofi acquired its predecessor company. Its lead product candidate, ozekibart, also known as INBRX-109, is a multivalent antibody designed to activate death receptor 5, which can trigger cancer cell death. In a randomized, placebo-controlled trial in conventional chondrosarcoma, a bone cancer with no approved systemic therapy, ozekibart extended the time patients lived without their disease progressing, and the company has sought U.S. approval for that use. It is also testing ozekibart with chemotherapy in Ewing sarcoma and colorectal cancer. Its second program, INBRX-106, is an immune-stimulating antibody studied with Keytruda in head and neck cancer. It has no product revenue and funds research through cash, borrowing and stock sales.
Inhibrx competes with larger oncology drug developers such as Merck and Bristol Myers Squibb, along with biotech companies developing treatments for sarcomas and solid tumors. Its edge rests on protein engineering that lets it build antibodies with multiple binding sites to boost activity, and an early position in a rare cancer with few treatment options. Investors who follow INBX stock tend to watch the U.S. regulatory review of ozekibart and plans for its commercial launch. Data from the Ewing sarcoma, colorectal cancer and head and neck studies are closely followed. Cash runway, debt and share dilution are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward INBX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
40Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Net income growth from the prior fiscal year to the latest.
EV/Revenue compares the whole company's value, debt included, with its sales.
5-year earnings growth evaluates long-term profit trajectory and consistency.
36 weighted scorers; 3 had no data today and are left out rather than counted as zero.
Technical · daily
22Pulling it up
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Directional, despite the name: the net 14-day move divided by the total Average True Range over the same days, compared with the stock's own history.
Williams %R (7-period) places the close within the last 7 periods' high-low range.
Holding it back
Performance versus SPY compares the stock's returns to the S&P 500 index.
Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.
Simple Moving Average (50-period) is a widely-watched intermediate-term trend gauge.
61 weighted scorers; 4 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 58
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 44 | 1 |
| Daily | 22 | 3 |
| Weekly | 34 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 38 |
| Nov 18, 2026 | 37 |
| Nov 17, 2026 | 38 |
| Nov 16, 2026 | 38 |
| Nov 15, 2026 | 39 |
| Nov 14, 2026 | 39 |
| Nov 13, 2026 | 39 |
| Nov 12, 2026 | 39 |
| Nov 11, 2026 | 47 |
| Nov 10, 2026 | 46 |
| Nov 8, 2026 | 41 |
| Nov 7, 2026 | 41 |
| Nov 6, 2026 | 42 |
| Nov 5, 2026 | 40 |
| Nov 4, 2026 | 43 |
| Nov 3, 2026 | 41 |
| Nov 2, 2026 | 39 |
| Nov 1, 2026 | 39 |
| Oct 31, 2026 | 38 |
| Oct 30, 2026 | 38 |
| Oct 29, 2026 | 38 |
| Oct 28, 2026 | 40 |
| Oct 27, 2026 | 47 |
| Oct 26, 2026 | 44 |
| Oct 25, 2026 | 47 |
| Oct 24, 2026 | 47 |
| Oct 23, 2026 | 47 |
| Oct 22, 2026 | 50 |
| Oct 21, 2026 | 50 |
| Oct 20, 2026 | 49 |
| Oct 19, 2026 | 46 |
| Oct 18, 2026 | 46 |
| Oct 17, 2026 | 46 |
| Oct 16, 2026 | 46 |
| Oct 15, 2026 | 46 |
| Oct 14, 2026 | 44 |
| Oct 13, 2026 | 44 |
| Oct 12, 2026 | 46 |
| Oct 11, 2026 | 48 |
| Oct 10, 2026 | 48 |
| Oct 9, 2026 | 48 |
| Oct 8, 2026 | 46 |
| Oct 7, 2026 | 46 |
| Oct 6, 2026 | 48 |
| Oct 5, 2026 | 46 |
| Oct 4, 2026 | 47 |
| Oct 3, 2026 | 47 |
| Oct 2, 2026 | 47 |
| Oct 1, 2026 | 47 |
| Sep 30, 2026 | 49 |
| Sep 29, 2026 | 52 |
| Sep 28, 2026 | 50 |
| Sep 27, 2026 | 48 |
| Sep 26, 2026 | 48 |
| Sep 25, 2026 | 48 |
| Sep 24, 2026 | 51 |
| Sep 23, 2026 | 51 |
| Sep 22, 2026 | 53 |
| Sep 21, 2026 | 52 |
| Sep 20, 2026 | 52 |
| Sep 19, 2026 | 52 |
| Sep 18, 2026 | 52 |
| Sep 17, 2026 | 51 |
| Sep 16, 2026 | 49 |
| Sep 15, 2026 | 50 |
| Sep 14, 2026 | 51 |
| Sep 13, 2026 | 51 |
| Sep 12, 2026 | 51 |
| Sep 11, 2026 | 51 |
| Sep 10, 2026 | 51 |
| Sep 9, 2026 | 52 |
| Sep 8, 2026 | 53 |
| Sep 7, 2026 | 54 |
| Sep 6, 2026 | 54 |
| Sep 5, 2026 | 54 |
| Sep 4, 2026 | 54 |
| Sep 3, 2026 | 55 |
| Sep 2, 2026 | 54 |
| Sep 1, 2026 | 54 |
| Aug 31, 2026 | 55 |
| Aug 30, 2026 | 55 |
| Aug 29, 2026 | 55 |
| Aug 28, 2026 | 55 |
| Aug 27, 2026 | 54 |
| Aug 26, 2026 | 55 |
| Aug 25, 2026 | 56 |
| Aug 24, 2026 | 54 |
| Aug 23, 2026 | 55 |
| Aug 22, 2026 | 55 |
Key facts
- Market cap
- $1.1B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 4.04
- Risk grade (1–10)
- 7
- Next earnings
- Nov 13, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| SVRA Savara | $1.1B | 38 |
| VOR Vor Biopharma | $1.1B | 43 |
| NKTR Nektar Therapeutics | $1.1B | 27 |
| ANRO Alto Neuroscience | $1.1B | 36 |
| DRTS Alpha Tau Medical | $1.0B | 30 |
| OMER Omeros | $1.0B | 57 |
Questions
What is INBX's stock rating today?
INBX scores 38/100 (Bearish) as of Nov 19, 2026: technical 29, fundamental 40, and news sentiment 58, which is shown but not counted. Scores are recomputed every night.
What does Inhibrx Biosciences do?
Inhibrx Biosciences (INBX) is a clinical-stage biotechnology company that develops antibody-based therapies for cancer. It was spun off when Sanofi acquired its predecessor company.
Is INBX stock a buy?
The score is not a buy or sell recommendation. A 38 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the INBX score calculated?
97 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/inbx/"><img src="https://stocksscores.com/stocks/inbx/badge.svg" alt="INBX stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/inbx/)